FDA approved the monotherapy for estrogen receptor (ER)–positive and HER2-negative metastatic breast cancer. The FDA approved imlunestrant (Inluriyo; Eli Lilly and Company) for treating adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback